Ana Collins-Smith

Ana Collins-Smith


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
ACAna Collins-Smith
Ana Collins-Smith
SJSangeeta K Jain
Sangeeta K Jain
SJSunil Kumar Jain
Sunil Kumar Jain
L-citrulline is a non-protein amino acid with critical roles in perinatal and neonatal physiology through the intestinal–renal arginine–citrulline axis and nitric oxide (NO) production. During pregnancy, L-citrulline supports placental angiogenesis, vascular adaptation, and fetal growth through augmentation of arginine availability and endothelial NO production. In neonates, particularly preterm infants, developmental immaturity of citrulline and arginine synthesis contributes to hypoargininemia and may increase susceptibility to necrotizing enterocolitis, bronchopulmonary dysplasia with pulmonary hypertension, sepsis, and impaired intestinal function. Although L-citrulline has emerged as a promising modulator of NO bioavailability, prior reviews have largely focused on either adult cardiovascular disease or isolated neonatal applications, with limited integration of its mechanistic and translational relevance across the perinatal and neonatal continuum. Collectively, current evidence supports L-citrulline as a promising translational target in maternal–fetal and neonatal medicine because of its central role in vascular, inflammatory, and metabolic regulation. However, adequately powered clinical trials are needed to define optimal dosing, timing, patient selection, and long-term outcomes before routine clinical implementation can be recommended. This review provides a comprehensive evaluation of L-citrulline metabolism and its therapeutic potential from pregnancy through neonatal life, with emphasis on the intestinal–renal arginine–citrulline axis, endothelial function, and NO-mediated vascular regulation. We specifically examine the role of citrulline in key pathophysiologic mechanisms underlying maternal and neonatal disease, including endothelial dysfunction, impaired NO bioavailability, inflammation, oxidative stress, and abnormal placental vascular remodeling.

7 October 2026 in Clinical Obstetrics and Gynecology
Verified
Journal Article
Closed access
FBFaranak Behnia
Faranak Behnia
CCCorey C. Clifford
Corey C. Clifford
SJSangeeta K Jain
Sangeeta K Jain
COChasey I. Omere
Chasey I. Omere
ACAna Collins-Smith
Ana Collins-Smith
LPLuis D. Pacheco
Luis D. Pacheco
Cardiomyopathies are uncommon but potentially life-threatening causes of cardiovascular disease in pregnancy. Pregnancy-associated hemodynamic changes may reveal unrecognized cardiomyopathy or exacerbate existing myocardial dysfunction. This review summarizes the diagnosis and management of dilated cardiomyopathy, hypertrophic cardiomyopathy, left ventricular hypertrabeculation/noncompaction cardiomyopathy, Takotsubo cardiomyopathy, and other rare cardiomyopathies during pregnancy. Our discussion will include pregnancy-specific hemodynamic considerations, risk stratification, medical management, labor and delivery planning, postpartum surveillance, and counseling regarding future pregnancy. This review does not address peripartum cardiomyopathy because it is considered separately.